Search
    ×

    Proposed Diabetes Spin

    FY20 BD Revenue

    FY20 BD Revenue in Pie Chart Image

    FY20 Diabetes Revenue by Region

    Diabetes Care Profile

    • FY20 revenues: ~ $1.1 billion

    • Global market share leader in insulin injection devices

    • Serving an estimated 30 million patients worldwide

    • 8 billion devices per year

    Q2FY21 Diabetes Spin Presentation

    Diabetes Spin Transaction Details

    • Expected to be implemented by means of 100% distribution of shares of a new publicly traded entity to BD stockholders

    • Intended to be tax-fee for U.S. income tax purposes

    • Anticipated completion in 1H of calendar year 2022

    • NewCo capital structure is expected to provide M&A flexibility for sustained organic and inorganic investment

    • BD expected to receive cash distribution from NewCo upon transaction close

    Global Diabetes Expenditures and Cost

    • $760 billion Annual global health expenditure on diabetes1

    • 10% of global health care costs is spent on diabetes1

    1 Source: https://www.diabetesatlas.org/en/sections/demographic-and-geographic-outline.html

    Spin off Strengthens Growth Profile

    NewCo

    • Builds upon focused purpose of improving care for patients with diabetes

    • Leverages global, market-leading position in pen needles

    • Allocates capital and resources more effectively to accelerate growth

    • Operationalizes strategic priorities more efficiently

    • Tightens connection of management compensation to corporate goals

    • Enhances ability to attract and retain talent

    • Seeks acquisitions that enhance its growth profile

    RemainCo

    • Strengthens mid-single-digit FX-neutral revenue growth and double-digit total return growth profile

    • Intensifies focus of human and financial capital on strategic businesses

    • Increases R&D efforts in strategic, higher-growth categories to accelerate our weighted average market growth rate

    • Advances RemainCo’s tuck-in M&A strategy

    • Preserves a flexible balance sheet and investment-grade credit ratings

    Management Team

    Chief Executive Officer of NewCo
    • Joined BD February 2021 and currently serves as Worldwide President, BD Diabetes Care.

    • Kurdikar served as CEO and president for Cardiac Science, a global manufacturer of automated external defibrillators (AEDs) until the sale of the company to ZOLL Medical Corporation, an Asahi Kasei Group Company. Previously, he was the general manager for the men’s health business at Boston Scientific and that business’s predecessor at American Medical Systems (AMS). He also held positions of increasing responsibility and leadership with Baxter.

    • Kurdikar earned an MBA from Washington University in St. Louis and a Ph.D. in Chemical Engineering from Purdue University. He is currently a member of the Board of Directors of LMG Holdings.

    Chief Financial Officer of NewCo
    • Elguicze has extensive experience in treasury, financial planning, reporting and analysis, and investor relations. 

    • He has joined BD from Teleflex, a global provider of medical technologies. Elguicze has served as Teleflex Treasurer and VP of IR since 2011.  He joined the organization in 2006 as Vice President of Financial Planning and Analysis. Prior to Teleflex, Elguicze held various senior positions within Motorola and was an auditor at PriceWaterhouse Coopers, LLC. 

    • Elguicze earned a Bachelors of Accounting at University of Scranton and an M.B.A. from St. Joseph's University.